Tweets
Ultrasound for ILD detection in RA đ«
Sens 88.6
Spe 92.8
NPV 91.4
PPV 90.7
While if abnormal or high suspicion, HRCT should be the reference, I see this as an interesting tool in clinics for quick screening
POS0180 #EULAR2025 @RheumNow https://t.co/pUy0ki7Y6S
Links:
Aurelie Najm @AurelieRheumo ( View Tweet )
10 months 2 weeks ago
#HOT topic
Lung đ« #ultrasound for #RA #ILD
#LUS B lines vs HRCT
Single site đ«đ· study
V sensitive & specific
đ€needs standardization & comparison in other groups
Abst#POS-180
#EULAR2025 @RheumNow @eular_org https://t.co/PwGE4rgk40
Janet Pope @Janetbirdope ( View Tweet )
10 months 2 weeks ago
Software enhances treat to target outcomes for #RA GoTreatIT
P0S0750 ##EULAR2025 @RheumNow https://t.co/GpihWr5KLA
Links:
Bella Mehta @bella_mehta ( View Tweet )
10 months 2 weeks ago
Does having a synovitis in a specific joint predicts Rx damage in that same joint?
Yes
Can US synovitis predict Rx progression better than clinical synovitis at the joint level?
Not really
At 1 year, only US synovitis is, both B-mode and Doppler ass w/ Rx prog, in particular https://t.co/Wu6dDqIUYn
Aurelie Najm @AurelieRheumo ( View Tweet )
10 months 2 weeks ago
Fascinating to see JAKi uptake in European JAK-pot centres
- tofa was already on the decline pre-ORAL Surveillance
- JAKi use (driven by upadacitinib) continues to grow, although maybe itâs slowed
Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821
David Liew @drdavidliew ( View Tweet )
10 months 2 weeks ago
Tenosynovitis of 5th compartment independently associated w/ D2T RA in a cohort of 90+ pts compared to established RA
Erosions, Tenosynovitis and Synovitis non associated with D2T phenotype
Itâd be interesting to see if this could predict D2T evolution in early RA pts
POS0185 https://t.co/faruOr3HhJ
Aurelie Najm @AurelieRheumo ( View Tweet )
10 months 2 weeks ago
RheumNowâs expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty
Dr. John Cush @RheumNow ( View Tweet )
10 months 2 weeks ago
In #SLE, #HCQ levels >1150âng/ml âtoxicity risk w/o added benefit. Levels 750-1150âng/ml linked to âdisease activity.
CKD stage â„3 doubled HCQ levels at same dose.
Supports monitoring & dose adjustment in CKD to balance safety & efficacy.
@RheumNow #EULAR2025 #OP0199
Mrinalini Dey @DrMiniDey ( View Tweet )
10 months 2 weeks ago
OP0176: Among D2T PsA pts, 43% lacked inflammation on imagingâdespite symptoms.
Clinical + US split them into PIPsA vs NIPsA, helping distinguish who needs escalation vs who doesnât.
A step toward smarter care in D2T PsA.
@RheumNow #EULAR2025 https://t.co/E9igwvDPPN
Jiha Lee @JihaRheum ( View Tweet )
10 months 2 weeks ago
New dual-action RA drug?
OP0193: CPLâ116 targets both JAK & ROCK.
In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs.
Is this a future option for RA-ILD or patients with comorbid CVD risk?
#EULAR2025 @RheumNow
Jiha Lee @JihaRheum ( View Tweet )
10 months 2 weeks ago
PHOENYCS GOđ: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) at wk48 vs PBO+SOC. DZP showed earlier & more sustained disease control, advancing T2T in SLE.
@RheumNow #EULAR2025 #OP0201 https://t.co/zuxBELxTDd
Mrinalini Dey @DrMiniDey ( View Tweet )
10 months 2 weeks ago
FAPI-PET/CT - detecting synovial and enthesial fibroblast activation- predicts the development of #psoriatic_arthritis in patients with psoriasis and arthralgia
âšïž A promising tool for early diagnosis of PsA
Giulia Corte et al.
OP#0174
#EULAR2025
@RheumNow https://t.co/QVmoECIhBI
Nelly ZIADE đ @Nellziade ( View Tweet )
10 months 2 weeks ago
